CheekAge: next-generation buccal epigenetic aging clock
GeroScience publication: Tally Health's CheekAge predicts all-cause mortality via cheek-swab DNA methylation.
OVUM Editorial·
Executive summary
GeroScience publication: Tally Health's CheekAge predicts all-cause mortality via cheek-swab DNA methylation. Companion paper extended the validation to mortality prediction in blood-based datasets — establishing buccal-swab epigenetic testing as a non-invasive biomarker of biological age. OVUM files this under prevention and biomarkers in women's health.
Key findings
- Companion paper extended the validation to mortality prediction in blood-based datasets — establishing buccal-swab epigenetic testing as a non-invasive biomarker of biological age.
Market implications
- Most aging biomarkers were validated in mixed or male populations, so women-specific reference ranges are still being established.
- A preventive product needs sex-specific evidence before an employer or payer will fund it.
- Measurement alone is widely available. What distinguishes a product is the intervention it triggers.
Interpretative layer
Professional access includes investor relevance, OVUM view, and category-level implications.
Source and methodology
Based on the linked publication, dated Jun 12, 2026.
Article summary
Companion paper extended the validation to mortality prediction in blood-based datasets — establishing buccal-swab epigenetic testing as a non-invasive biomarker of biological age.